Pathos AI and Bristol Myers Squibb Launch Alzheimer’s Collaboration

Pathos AI collaboration reported

Pathos AI has launched a multi-year collaboration with Bristol Myers Squibb to advance Alzheimer’s drug development, according to Pharmaceutical Executive Daily, published by Pharmexec.

The collaboration was included in Pharmexec’s daily coverage alongside other healthcare and drug-development developments involving the companies named in the report. The publisher identifies Alzheimer’s drug development as the focus of the Pathos AI and Bristol Myers Squibb collaboration.

For medical and pharmaceutical sales professionals following partnership activity, the announcement centers on a collaboration between Pathos AI and Bristol Myers Squibb in a defined therapeutic area. Pharmexec describes the arrangement as multi-year and ties it directly to efforts to advance Alzheimer’s drug development.

Additional Pathos AI partnership activity

Pharmexec also reports that Pathos AI launched a multi-year collaboration with Tempus AI to advance Alzheimer’s drug development. The daily report names both Bristol Myers Squibb and Tempus AI in connection with Pathos AI’s collaboration activity.

The report does not provide further details in the supplied summary on the individual responsibilities of the organizations, specific programs, development milestones, or terms of the collaborations. The available information identifies the companies involved, the multi-year nature of the collaborations, and their stated Alzheimer’s drug-development focus.

Other Bristol Myers Squibb coverage in the daily report

Separately, Pharmexec reports that Bristol Myers Squibb disclosed a patient death in its Phase I CAR-T multiple sclerosis trial. This clinical-trial disclosure is distinct from the Pathos AI collaboration and concerns multiple sclerosis rather than Alzheimer’s drug development.

The daily report also includes a discussion with health economist Dr. Nadine Zawadzki on how value is defined across healthcare, according to Pharmexec. That discussion is likewise separate from the Pathos AI collaborations.

Reported details

• Pathos AI launched a multi-year collaboration with Bristol Myers Squibb.
• Pharmexec says the collaboration is intended to advance Alzheimer’s drug development.
• Pathos AI also launched a multi-year collaboration with Tempus AI, according to Pharmexec.
• Pharmexec separately reported Bristol Myers Squibb’s disclosure involving its Phase I CAR-T multiple sclerosis trial.